Do analysts recommend FTLF or BCTX?

FitLife Brands currently has a consensus target price of $21.50, indicating a potential upside of 118.27%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts clearly believe FitLife Brands is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer FTLF or BCTX?

In the previous week, FitLife Brands and FitLife Brands both had 3 articles in the media. FitLife Brands' average media sentiment score of 0.87 beat Briacell Therap's score of 0.47 indicating that FitLife Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FitLife Brands 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BCTX or ETHZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BCTX or ETHZ more profitable?

Briacell Therap's return on equity of -173.08% beat Flag Ship Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -173.08% -139.64% Flag Ship Acquisition N/A -185.71% -83.12%

Do analysts rate ICCC or BCTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ICCC or BCTX more profitable?

Briacell Therap has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell -1.82% -1.88% -1.22% Briacell Therap N/A -173.08% -139.64%

Do analysts rate THAR or BCTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, THAR or BCTX?

Tharimmune is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Briacell Therap N/A N/A -$26.31M -$23.33 N/A

Is THAR or BCTX more profitable?

Briacell Therap's return on equity of -173.08% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Briacell Therap N/A -173.08% -139.64%

Do analysts recommend PMN or BCTX?

Promis Neurosciences currently has a consensus target price of $26.50, suggesting a potential upside of 167.95%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Promis Neurosciences is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Promis Neurosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, PMN or BCTX?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A Briacell Therap N/A N/A -$26.31M -$23.33 N/A

Is PMN or BCTX more profitable?

Briacell Therap's return on equity of -173.08% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -237.99% -151.04% Briacell Therap N/A -173.08% -139.64%

Does the media refer more to PMN or BCTX?

In the previous week, Briacell Therap had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for Briacell Therap and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.63 beat Briacell Therap's score of 0.47 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Briacell Therap (BCTX) Competitors

$3.28 -0.03 (-0.88%)

As of 02:23 PM Eastern

Compare

BCTX vs. FTLF, ETHZ, ICCC, THAR, and PMN

Should you buy Briacell Therap stock or one of its competitors? MarketBeat compares Briacell Therap with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Briacell Therap include FitLife Brands (FTLF), Flag Ship Acquisition (ETHZ), ImmuCell (ICCC), Tharimmune (THAR), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.

How does Briacell Therap compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

FitLife Brands has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

2.3% of FitLife Brands shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 61.4% of FitLife Brands shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, FitLife Brands and FitLife Brands both had 3 articles in the media. FitLife Brands' average media sentiment score of 0.87 beat Briacell Therap's score of 0.47 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FitLife Brands	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

FitLife Brands has a net margin of 6.64% compared to Briacell Therap's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Briacell Therap	N/A	-173.08%	-139.64%

FitLife Brands currently has a consensus target price of $21.50, indicating a potential upside of 118.27%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts clearly believe FitLife Brands is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

FitLife Brands has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.14	$6.33M	$0.60	16.42
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A

Summary

FitLife Brands beats Briacell Therap on 12 of the 14 factors compared between the two stocks.

How does Briacell Therap compare to Flag Ship Acquisition?

Briacell Therap (NASDAQ:BCTX) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Briacell Therap has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Flag Ship Acquisition has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Briacell Therap had 3 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 3 mentions for Briacell Therap and 0 mentions for Flag Ship Acquisition. Briacell Therap's average media sentiment score of 0.47 beat Flag Ship Acquisition's score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Overall Sentiment
Briacell Therap	Neutral
Flag Ship Acquisition	Neutral

Flag Ship Acquisition has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
Flag Ship Acquisition	$4.11M	22.53	-$6.17M	-$159.65	N/A

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 4.1% of Flag Ship Acquisition shares are held by institutional investors. 0.7% of Briacell Therap shares are held by company insiders. Comparatively, 15.1% of Flag Ship Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Briacell Therap's return on equity of -173.08% beat Flag Ship Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
Flag Ship Acquisition	N/A	-185.71%	-83.12%

Summary

Briacell Therap beats Flag Ship Acquisition on 6 of the 11 factors compared between the two stocks.

How does Briacell Therap compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Briacell Therap had 3 more articles in the media than ImmuCell. MarketBeat recorded 3 mentions for Briacell Therap and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.44 beat Briacell Therap's score of 0.47 indicating that ImmuCell is being referred to more favorably in the media.

Company	Overall Sentiment
ImmuCell	Positive
Briacell Therap	Neutral

ImmuCell has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Briacell Therap has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Briacell Therap	N/A	-173.08%	-139.64%

ImmuCell has higher revenue and earnings than Briacell Therap. ImmuCell is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$29.93M	3.00	-$1.04M	-$0.06	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A

Summary

ImmuCell beats Briacell Therap on 7 of the 12 factors compared between the two stocks.

How does Briacell Therap compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Tharimmune has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Briacell Therap's return on equity of -173.08% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Briacell Therap	N/A	-173.08%	-139.64%

Tharimmune is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Briacell Therap had 3 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Briacell Therap and 0 mentions for Tharimmune. Briacell Therap's average media sentiment score of 0.47 beat Tharimmune's score of 0.00 indicating that Briacell Therap is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Briacell Therap	Neutral

Summary

Briacell Therap beats Tharimmune on 6 of the 10 factors compared between the two stocks.

How does Briacell Therap compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

In the previous week, Briacell Therap had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for Briacell Therap and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.63 beat Briacell Therap's score of 0.47 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 0.7% of Briacell Therap shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Promis Neurosciences has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Briacell Therap's return on equity of -173.08% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Briacell Therap	N/A	-173.08%	-139.64%

Promis Neurosciences currently has a consensus target price of $26.50, suggesting a potential upside of 167.95%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Promis Neurosciences is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Promis Neurosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A

Summary

Promis Neurosciences beats Briacell Therap on 8 of the 14 factors compared between the two stocks.

Get Briacell Therap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCTX vs. The Competition

Export

Metric	Briacell Therap	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.79M	$3.33B	$6.42B	$12.48B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.14	18.86	23.85	24.39
Price / Sales	N/A	319.25	520.29	116.29
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.36	6.82	10.04	6.74
Net Income	-$26.31M	$24.09M	$3.56B	$337.03M
7 Day Performance	-8.35%	-2.69%	-1.09%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-90.03%	48.33%	28.56%	34.29%

Briacell Therap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCTX Briacell Therap	0.578 of 5 stars	$3.28 -0.9%	N/A	-90.2%	$23.79M	N/A	N/A	8
FTLF FitLife Brands	4.5116 of 5 stars	$9.91 +2.0%	$21.50 +117.0%	-30.3%	$93.06M	$81.46M	16.41	20
ETHZ Flag Ship Acquisition	N/A	$4.77 +4.4%	N/A	N/A	$90.69M	$4.11M	N/A	7
ICCC ImmuCell	0.9162 of 5 stars	$9.91 +1.2%	N/A	+46.3%	$89.69M	$27.64M	N/A	70	Positive News Short Interest Decrease
THAR Tharimmune	N/A	$2.37 -15.5%	N/A	+51.4%	$89.42M	N/A	N/A	2	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCTX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Briacell Therap (BCTX) Competitors

BCTX vs. FTLF, ETHZ, ICCC, THAR, and PMN

How does Briacell Therap compare to FitLife Brands?

Summary

How does Briacell Therap compare to Flag Ship Acquisition?

Summary

How does Briacell Therap compare to ImmuCell?

Summary

How does Briacell Therap compare to Tharimmune?

Summary

How does Briacell Therap compare to Promis Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Briacell Therap (BCTX) Competitors

BCTX vs. FTLF, ETHZ, ICCC, THAR, and PMN

How does Briacell Therap compare to FitLife Brands?

Which has more volatility & risk, FTLF or BCTX?

Do institutionals & insiders believe in FTLF or BCTX?

Does the media prefer FTLF or BCTX?

Is FTLF or BCTX more profitable?

Do analysts recommend FTLF or BCTX?

Which has better earnings & valuation, FTLF or BCTX?

Summary

How does Briacell Therap compare to Flag Ship Acquisition?

Which has more risk & volatility, BCTX or ETHZ?

Do analysts rate BCTX or ETHZ?

Does the media favor BCTX or ETHZ?

Which has preferable earnings & valuation, BCTX or ETHZ?

Do insiders & institutionals have more ownership in BCTX or ETHZ?

Is BCTX or ETHZ more profitable?

Summary

How does Briacell Therap compare to ImmuCell?

Do institutionals and insiders have more ownership in ICCC or BCTX?

Does the media prefer ICCC or BCTX?

Which has more volatility & risk, ICCC or BCTX?

Do analysts rate ICCC or BCTX?

Is ICCC or BCTX more profitable?

Which has better earnings and valuation, ICCC or BCTX?

Summary

How does Briacell Therap compare to Tharimmune?

Do institutionals & insiders have more ownership in THAR or BCTX?

Which has more risk and volatility, THAR or BCTX?

Is THAR or BCTX more profitable?

Which has higher valuation and earnings, THAR or BCTX?

Do analysts rate THAR or BCTX?

Does the media prefer THAR or BCTX?

Summary

How does Briacell Therap compare to Promis Neurosciences?

Does the media refer more to PMN or BCTX?

Do institutionals & insiders hold more shares of PMN or BCTX?

Which has more risk and volatility, PMN or BCTX?

Is PMN or BCTX more profitable?

Do analysts recommend PMN or BCTX?

Which has stronger valuation and earnings, PMN or BCTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools